Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards and emphasizes the importance of core values in shaping organizational culture. He highlights his approach to hiring, focusing on finding individuals who are passionate about making an impact over titles. Overall, the discussion provides valuable insights into the evolving landscape of cancer treatment. Biography: Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, and served as Head of Business Development and Medical Affairs for Cadence Pharmaceuticals. Robert also worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm, where he was involved in several pharmaceutical and biotechnology investments including Cadence Pharmaceuticals (purchased by Mallinckrodt), Incline Therapeutics (purchased by The Medicines Company), Alnara Pharmaceuticals (purchased by Eli Lilly), and Collegium Pharmaceuticals. Robert also has strategy consulting experience at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School. Robert serves as the Board Chair of Enara Bio, a UK-based biotechnology company focused on non-classical HLA targets for immuno-oncology approaches. He is also a member of the Executive Committee of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.